Clinical Scorecard: Evaluation of Innate and Adaptive Immune Responses to the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccine: Insights from an Ancillary Study of the EBL2001 Phase 2 Trial

At a Glance

Key Highlights

• The Ad26.ZEBOV, MVA-BN-Filo vaccine regimen elicits early serum inflammatory/activation markers mainly 1 day after Ad26.ZEBOV prime.
• Durable EBOV-specific T-cell proliferation and cytotoxic CD8+ T-cell responses persist up to 6 months postvaccination.
• Integrated analyses show correlations between EBOV-specific CD8+ T-cell cytotoxicity and lower IL-8 inflammatory marker levels postvaccination.

Guideline-Based Recommendations

Diagnosis

• Use serological assays such as EBOV GP Filovirus Animal Non-Clinical Group (FANG) ELISA to measure EBOV GP-specific IgG.
• Assess neutralizing antibody titers by pseudovirion neutralization assays.

Management

• Administer a heterologous 2-dose vaccine regimen: Ad26.ZEBOV prime followed by MVA-BN-Filo boost at intervals of 28, 56, or 84 days.
• Monitor for adverse events, including neurological serious adverse events, with temporary suspension protocols as needed.

Monitoring & Follow-up

• Evaluate serum biomarkers of activation/inflammation using multiplex assays (e.g., Luminex) early postvaccination.
• Assess T-cell responses including phenotype, cytokine production, proliferation, and cytotoxic potential longitudinally.
• Perform integrated data analyses correlating cellular and humoral immune responses.

Risks

• Potential for neurological serious adverse events requiring vaccination suspension and regulatory review.
• Inflammatory responses postvaccination should be monitored to understand vaccine reactogenicity.

Patient & Prescribing Data

Healthy European adults enrolled in phase 2 clinical trial

The vaccine regimen is safe, well tolerated, and induces robust innate, humoral, and cellular immune responses that persist for at least one year.

Clinical Best Practices

• Use a heterologous prime-boost vaccination schedule with Ad26.ZEBOV followed by MVA-BN-Filo for optimal immunogenicity.
• Monitor both humoral and cellular immune responses to comprehensively evaluate vaccine efficacy.
• Incorporate biomarker and T-cell functional assays to understand immune correlates of protection.
• Ensure ethical approval and informed consent in clinical trial settings.
• Be vigilant for adverse events and have protocols for temporary suspension and regulatory communication.

References

• World Health Organization Ebola Outbreak News
• EBL2001 Phase 2 Trial ClinicalTrials.gov